Combination of medication for antivirus in use for eye region and preparation method

An antiviral drug and composition technology, applied in the directions of drug combinations, antiviral agents, pharmaceutical formulations, etc., can solve the problems of poor controllability of preparation quality standards, difficult to achieve uniform administration, unstable gel state, etc. High standard controllability, maintaining effective drug concentration, and reducing the effect of dosing frequency

Inactive Publication Date: 2005-06-15
成都三明药物研究所
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is a gel in vitro, the gel state is unstable, and the quality control of the preparation is poor. The method of use is to apply a small amount to the lower conjunctival sac each time. Causes pollution during use, and because it is applied in the lower conjunctival sac, it is difficult to achieve uniform drug administration, resulting in inconstant dosage and uneven application, which is inconvenient to use and easy to cause waste

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1 The preparation of medicine of the present invention

[0024] Prescription: Ganciclovir: 0.1g; Carbomer 940: 0.40g; Hypromellose: 1.20g; Disodium hydrogen phosphate: 0.25g; Sodium dihydrogen phosphate: 0.50g; Sodium chloride: 0.5g 1. Ethylparaben: 0.03g; appropriate amount of sodium hydroxide to adjust the pH value to 6.5.

[0025] With above-mentioned formula by following preparation technology:

[0026] a. Dissolve disodium hydrogen phosphate, sodium dihydrogen phosphate and methyl cellulose in appropriate amount of water for injection to form a transparent solution.

[0027] b. Take carbomer and add it to an appropriate amount of water for injection to swell. After the swelling is complete, add it to the transparent solution in step a above, and keep stirring to form a transparent solution.

[0028] c. Add ethylparaben and sodium chloride to an appropriate amount of water for injection until completely dissolved, and stir evenly, then add to the transp...

Embodiment 2

[0031] Embodiment 2 The preparation of medicine of the present invention

[0032]Prescription: Ganciclovir: 0.05g; Carbomer 940: 0.30g; Hypromellose: 2.20g; Disodium hydrogen phosphate: 0.25g; Sodium dihydrogen phosphate: 0.50g; Sodium chloride: 0.5g ;

[0033] Above-mentioned formula is prepared by the technique of embodiment 1.

Embodiment 3

[0034] Embodiment 3 Preparation of the pharmaceutical composition of the present invention

[0035] Prescription: Ganciclovir: 0.05g; Carbomer 940: 0.50g; Hypromellose 1.30g; Disodium hydrogen phosphate: 0.20g; Sodium dihydrogen phosphate: 0.60g; Sodium chloride: 0.5g; Dumiphen: 0.03g; appropriate amount of sodium hydroxide to adjust the pH to 6.0.

[0036] The above formula is prepared according to the preparation process of Example 1, filled after passing the inspection, and autoclaved for subsequent use.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a pharmaceutical composition and a preparation method thereof, specifically, an ophthalmic sustained-release preparation containing ganciclovir and a preparation method thereof. It is an ophthalmic sustained-release preparation made from ganciclovir, carbomer, hydroxypropylmethylcellulose and commonly used pharmaceutical ophthalmic preparation auxiliary materials. The eye drops prepared by the in-situ gelation technology of the present invention have stable quality, less content of main drug ganciclovir, can maintain effective drug concentration for a long time, improve bioavailability, and reduce eye irritation. The drug administration frequency is reduced, the use is convenient, the preparation process is highly controllable, the industrial production capacity is easy to form, the production cost is reduced, and a new drug selection is provided for clinical use.

Description

technical field [0001] The invention relates to an antiviral drug composition for eyes, in particular to an ophthalmic sustained-release preparation containing ganciclovir and a preparation method thereof. Background technique [0002] At present, the two most commonly used dosage forms of drugs for the treatment of eye infections are: solution and ophthalmic ointment. Solution-type eye drops, the principle of action is: after dripping into the eyes, the drug will be delivered with the secretion of tears, which is characterized by uniform distribution, but due to the continuous secretion of tears in the conjunctival sac and rapid removal from the nasolacrimal duct, it will be in the conjunctiva. The intracapsular residence time is very short, so the intraocular bioavailability is very low. Frequent administration is required to maintain normal drug concentration, which brings great inconvenience to patients, and the increase in the number of administrations greatly increase...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/00A61K31/522A61P31/12A61P37/02
Inventor 阳向波谢炜
Owner 成都三明药物研究所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products